ABSTRACT
INTRODUCTION
Although liver transplantation has become a standard procedure for patients with liver failure, a number of issues in the management of these cases remain to be addressed, in particular organ shortage and poor outcome in patients not supported by liver transplant. In order to overcome these problems, alternative approaches have been proposed, such as auxiliary and split-liver transplantation, procurement from living donors, isolated cell transplantation, transgenic xenotransplantation or extracorporal liver support. In particular, cell-based therapies, comprising isolated hepatocyte transplantation (2) . Recent advances in the liver repopulation field and the considerable excitement surrounding the use of hematopoietic stem cells (HSC) for regenerative medicine allow us to explore new possibilities.
Several studies performed in animal models highlighted the potential of HSC to both differentiate into hematopoietic cell lineages and apparently transdifferentiated into nonhematopoietic cells, such as hepatocytes, neurons, astrocytes, skeletal muscle and cardiac muscle cells, pulmonary epithelium, renal tubular cells and pancreatic islet cells (3) . The potential use of UCB in the treatment of hepatic failure (a major problem worldwide) has been a research focus for several years now. Recent studies have identified UCB as a possible source of hepatic progenitor cells that can be delivered to the liver by portal or systemic circulation. These types of investigations have typically involved damaging the liver in some manner (partial hepatectomy, irradiation or chemically), and then examining for the presence of hepatic progenitor cells (5,14 ) . In the present study, we want to identify whether UCB, which are a rich source of stem cells, would be able to differentiate into hepatocytes when infused intravenously in CCl4 mice model.
MATERIALS & METHODS

Materials
1-Animals
Albino female mice 6 weeks old, 40 gm weight were used in this study. Animals were brought from the Ophthalmic Research Institute Center for experimental animals in Giza, were acclimatized for one week and kept with free access to standard pellet animal diet and tap water under controlled conditions of room temperature. Mice were equally divided into the following four groups, each containing 13 mice: Group (1): immediately treated with stem cells after receiving CCl 4 . Group (2): treated with stem cells 1 week after receiving the first dose of CCl 4. Group (3): not treated with stem cells (received only CCl 4 in a dose similar to that of G1 and G2), as a control group. Group (4): received only corn oil (solvent of CCl 4 ), as another control group.
2-Cord blood collection
Sterile collection tubes containing citrate phosphate dextrose adenine-l (CPDA-l) anticoagulant were used for collection of the cord blood. Sterile syringe and disposable gloves was used. cells were assessed by putting the sample on automated cell counters. -The quality of the isolated CD34+ cells were determined by using tyrpan blue dye exclusion test: the viable cells were not stained (13) .
3-Reagents
5-Transplantation of HUCB stem cells
After preparation of UCB stem cells, a dose of 10 6 UCB stem cells/mice were injected IV in the dorsal tail vein after inducing venodilataion by rubbing the tail with alcohol. 6-Handling of the liver specimens -For each mouse, a paraffin block from the liver was prepared.
-From each paraffin block, serial 5 µ thick tissue sections were obtained and processed through the following:
6-1-Histopathology
Two 5 µ paraffin sections from each block were stained with hematoxylin and eosin
. Morphological analysis was performed to determine the liver architecture, portal tract inflammation, portal tract fibrosis, liver fibrosis and piecemeal necrosis. In addition, the extent of fibrosis was further confirmed on masson trichrome.
6-2-Immunohistochemistry
Five sections were mounted on the positive charged slides for IHC and stained with monoclonal mouse antihuman hepatocyte.
Controls
In each staining session: a slide of human liver (obtained from Pathology Lab., Suez Canal University Hospital) known to be positive for the mouse monoclonal anti-human hepatocyte was used as a positive control. A slide of non-treated mice liver known to be negative for the monoclonal mouse anti-human hepatocyte was used as a negative control.
Then the IHC stained slides were examined to determine: the presence of immunopositive human hepatocyte in the mice liver by the presence of distinct, cytoplasmic, granular brownish staining (1) .
7-Image-based analysis system
The percentage of immunopositive human hepatocyte in the liver sections of the mice treated with human CD34+ stem cells was calculated using image-based analysis system (Supereye Heidisoft). The number of immunopositive cells was estimated by manual counting. Then it was divided by the total number of cells giving the percentage of immunopositive cells. Fifteen captures were taken per mice (five captures per section and three sections per mice).
8-Statistical analysis
Data were analyzed with the SPSS statistical software program (SPSS Inc.) and all summary statistics for numerical data (quantitative continuous data) were presented as means± standard deviation (SD). Serum ALT, albumin, total and direct bilirubin were compared among the studied group with analysis of variance (ANOVA), followed by posthoc test. The level of significance was at (p<0.05). Frequency and percentage were done for qualitative data. Chi. Square test was used to assess the difference among the four groups for qualitative nominal data.
9-Ethical consideration
Informed consent was taken from each pregnant woman before umbilical cord blood sample was taken. Patient was informed that there was no risk about her health or her child health from taking UCB sample. Any woman has the right to withdraw from the study without giving reasons. Animals was handled gently, housed with suitable environmental and nutritional conditions, assessed for general health and body weight and anesthetized before sacrifice.
RESULTS
Chemistry: level of ALT and albumin were significantly different among the four groups, table (1) . Pathology Immunohistochemical staining findings
1-Differentiation of CD34+ cells into human hepatocytes
Liver sections from the negative control group (G4) shows absence of immunoreactivity for the anti-human hepatocyte (Fig. 1) , while strong cytoplasmic granular staining is encountered in the section of human liver (Fig. 2) . (Fig. 3) . This indicates that human CD34+ cells circulating into the liver of the mice "transdifferentiated" within the mouse injured liver microenvironment.
2-Image analysis
It is found that the percentage of human hepatocyte in injured mice liver was variable in the two groups injected with the human CD34+ stem cells (G1,G2) as estimated by manual counting operation using image-based analysis system. The difference in the percentage of immunopositive cells is statistically significant between G1 and G2 (table 3) . 
DISCUSSION
Therefore, this study was designed to determine the mechanism of hepatic response to UCB stem cells transplantation in CCl 4 injured liver. It consisted of four groups of nonimmunosupressed mice; G1 was treated with stem cells immediately after CCl 4 injection, G2 was treated with stem cells after one week from the first dose of CCl 4 injection, G3 was not treated with stem cells and received CCl 4 only and G4 not treated with stem cells and did not receive CCl4 (control group).
There were no previous records demonstrating that CCl4 affects the viability or the function of stem cells, therefore in this study we injected stem cells immediately (G1) and 1 week after receiving CCl4 (G2) and was continuously administrated for 10 weeks.
Before beginning this work, a pilot study was effectuated based on the work of Fang et al.
(4) . The induction of hepatic fibrosis was achieved after 10 weeks contrary to the previous work (4) using 5 weeks. This may be due to the different mice generation, and different temperature and humidity in addition to the purity and efficacy of the drug (CCl 4 ).
The time of HUCB stem cells administration, whether immediately or after one week is an important determinant for their therapeutic effects. Shi et al. (10) found that delaying stem cell administration by one week after CCl 4 challenge did not affect their engraftment, but hampered their ability to prevent disease progression. This may be caused by the irreversible course of CCl 4 -induced injury, which, once it happened, cannot be rescued by HUCB stem cells administration.
The absence of rejection to UCB stem cells may be due to unique immunological properties of both the stem cell and non-stem cell components of cord blood, it may be possible to utilize allogeneic cells for regenerative applications without needing to fully compromise the recipient immune system (9) . In the current study, the degree of liver function and fibrosis were better in G1 than in G2 but still better in G2 than in G3. ALT was significantly lower in G1 mice and in G2 mice compared to that in G3, However, ALT level in G1 is less than that in G2 when compared with G3. Fang et al.
(4) and Yagi et al. (19) found that the level of the ALT in mice treated with stem cells transplantation after CCl 4 administration were significantly lower compared to those of only CCl 4 group without stem cells transplantation.
Therefore, they hypothesized that transplantation of UCB stem cells can promote proliferation of the functional hepatic cells of the host.
In this study, there were no statistical significant differences in serum total and direct bilirubin among mice in G1, G2 and G3. A similar observation was ruled by Fang et al. (4) who found that serum total and direct bilirubin levels were similar among mice treated and those not treated with stem cells along with CCl 4 . The explanation is unknown but possibly this may be due to failure of the new hepatocytes developed from the transplanted stem cells to uptake and/or to conjugate and/or secrete bilirubin.
In the current study, albumin was significantly more in G1 mice and in G2 mice compared to that in G3. However, albumin level in G1 was significantly more than that in G2. Similarily, Yagi et al. (19) found that transplantation of the bone marrow stem cells into CCl 4 liver-injured rats restored their serum albumin level. This is a good indicator that the transdifferentiated hepatocytes were functional as the hepatocytes were the only source of albumin in mice as well as humans.
In this study, data of histopathology was represented as the following items: liver architecture and liver cells changes, portal tract inflammation, piecemeal necrosis, portal tract fibrosis and bridging fibrosis and was not represented as grading or scoring because Knodell score is a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis and not used in CCl 4 induced liver fibrosis (6) . It was found that the liver injury in treated groups were lower than that of nontreated group. However, the hepatic tissue recovery from damage was much improved in G1 mice when compared with G2. This indicates that UCB stem cells had the ability to rescue CCl 4 -damaged liver, which might contribute to the restoration of organ function.
Histological examination revealed that 10 weeks of receiving CCl 4 without stem cells treatment (G3) showed preserved liver architecture but with varying degree of cells changes, inflammation of the portal tract, piecemeal necrosis, portal tract fibrosis and bridging fibrosis in all mice of the group. This is similar to Fang et al.
(4) who found that areas of liver degeneration and necrosis in mice received CCl 4 were significant more than stem cells treated mice.
Whereas in G1 which was treated with HUCBSCs immediately after receiving CCl 4 , the liver architecture was preserved with 28.6% having no liver cells changes and 14.3% having no portal tract inflammation. Neither piecemeal necrosis nor portal tract fibrosis was found in any of the liver specimens in this group. Also 42.9% had no bridging fibrosis. Sakaida et al. (8) found that the hepatic damage improvement in the histological examinations was much better in the stem cells treated mice Animals treated with stem cells one week after receiving the first CCl 4 dose (G2) in spite of having preserved liver architecture yet all had liver cells changes in the form of mild liver cells ballooning in 28.6% and moderate liver cells ballooning in 71.4%. In addition portal tract inflammation was moderate in 42.9%, marked in 57.1%. Piecemeal necrosis was mild in 42.9%, moderate in 57.1%. Portal tract fibrosis was absent from all liver specimens of this group, but bridging fibrosis was present in all of them with short fibrous septum in 42.9% and mild bridging in 57.1%.
When compared with G3 mice, the portal tract inflammation, piecemeal necrosis and bridging fibrosis were statistical significantly lower in G1 and G2 than in G3. However, piecemeal necrosis and liver fibrosis were more in G2 than in G1. These data showed that hepatic tissue recovery from damage was much better in G1 mice when compared with G2 ones.
In the present study, CD34+ UCB cells converted into human hepatocytes, suggesting that CD34+ cells are rich in hepatic progenitor cells. Livers from mice in the treated groups were found to contain cells that stained positively for anti-human hepatocyte antibody, while none of the control mouse livers demonstrating such staining. Normal human liver served as the positive control for this analysis. Only hepatocytes, not bile duct cells or other non-parenchymal cells, were positively stained in the human liver section. It was found that the percentage of human hepatocyte in injured mice liver was variable in the two groups about 3.49% in G1 and 1.81% in G2.
Our results were identical to Shyu et al.
(11) who had the same finding that UCB stem cells have the capacity to differentiate into cells with human hepatocyte characteristics in mouse liver following injury and found that the ratio of human hepatocyte repopulation was 2.45%, 6 weeks after UCB cell injection. Di Campi et al. found that human stem cells were able to transdifferentiated into hepatocytes, to improve liver regeneration after damage and the percentage of human hepatocyte in mice liver was 1.1%, after 4 weeks of UCB stem cell injection.
Tanabe et al. (14) revealed that the CD34+UCB cells are rich fractions in hepatic progenitor cells and found that human hepatocyte specific antigen positive cells were distributed throughout the mice liver after CCl 4 injury. Of 5542 hepatocytes, 90 (1.7%) hepatocytes expressed humanspecific antigen when stained with anti-human hepatocyte monoclonal antibody one month after transplantation of CD34+UCB cells.
The 
